Snapshot
- Page Path
-
- HOME
- ARTICLE CATEGORY
- Snapshot
- Snapshot
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Chaerin Woo, Won-Il Jeong
- Clin Mol Hepatol. 2024;30(2):299-302. Published online February 19, 2024
-
View: 943 Download: 47
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- Young Chang, Soung Won Jeong, Jae Young Jang
- Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023
-
View: 1558 Download: 110
- The role of the hepatic autonomic nervous system
- Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin
- Clin Mol Hepatol. 2023;29(4):1052-1055. Published online July 25, 2023
-
View: 1636 Download: 54
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Soon Kyu Lee, Jung Hyun Kwon
- Clin Mol Hepatol. 2023;29(3):825-827. Published online May 31, 2023
-
View: 2105 Download: 87
- Systemic therapy in advanced hepatocellular carcinoma
- Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang
- Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023
-
View: 3239 Download: 158 Web of Science: 3 Crossref: 3
- Epidemiology and updated management for autoimmune liver disease
- Nae-Yun Heo, Haeryoung Kim
- Clin Mol Hepatol. 2023;29(1):194-196. Published online December 14, 2022
-
View: 3906 Download: 144 Web of Science: 2 Crossref: 4
- Personalized medicine in nonalcoholic fatty liver disease
- Carlos J. Pirola, Silvia Sookoian
- Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022
-
View: 3553 Download: 135 Web of Science: 4 Crossref: 4
- Microbiome and metabolomics in alcoholic liver disease
- Raja Ganesan, Ki Tae Suk
- Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022
-
View: 4299 Download: 149 Web of Science: 3 Crossref: 4
- Acute on chronic liver failure in cirrhosis
- Marta Tonon, Salvatore Piano
- Clin Mol Hepatol. 2022;28(2):273-275. Published online February 14, 2022
-
View: 5160 Download: 219 Web of Science: 1 Crossref: 1
- Current status and outcome of liver transplantation in South Korea
- Ho Joong Choi
- Clin Mol Hepatol. 2022;28(1):117-119. Published online December 7, 2021
-
View: 4982 Download: 87 Web of Science: 7 Crossref: 9
- History and future of hepatitis B virus control in South Korea
- Do Young Kim
- Clin Mol Hepatol. 2021;27(4):620-622. Published online September 23, 2021
-
DOI: https://doi.org/10.3350/cmh.2021.0277 Correction in: Clin Mol Hepatol 2022;28(4):939
-
View: 6851 Download: 153 Web of Science: 8 Crossref: 8
- Hepatocellular carcinoma statistics in South Korea
- Young Eun Chon, Soung Won Jeong, Dae Won Jun
- Clin Mol Hepatol. 2021;27(3):512-514. Published online June 21, 2021
-
View: 5759 Download: 172 Web of Science: 24 Crossref: 24
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen
- Received December 21, 2023 Accepted December 28, 2023
-
DOI: https://doi.org/10.3350/cmh.2023.0555 [Epub ahead of print]
-
View: 1715 Download: 49
- EXAMINING THE THERAPEUTIC LANDSCAPE OF BETA-BLOCKERS IN PORTAL HYPERTENSION
- Anna Brujats, Càndid Villanueva
- Received February 24, 2024 Accepted March 4, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0144 [Accepted]
-
View: 418 Download: 19
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor8.9First decision
09 Days
Publication after acceptance
04 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2022-2024)
|
|||||||
